| 71.83 -1.06 (-1.45%) | 10-07 13:49 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 88.36 |
1-year : | 91.34 |
| Resists | First : | 75.65 |
Second : | 78.2 |
| Pivot price | 74.11 |
|||
| Supports | First : | 71.51 |
Second : | 59.49 |
| MAs | MA(5) : | 72.4 |
MA(20) : | 74.29 |
| MA(100) : | 73.05  |
MA(250) : | 68.19 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 8.2 |
D(3) : | 10.2 |
| RSI | RSI(14): 37.2 |
|||
| 52-week | High : | 84.88 | Low : | 45.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ITCI ] has closed above bottom band by 13.5%. Bollinger Bands are 12.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 73.14 - 73.62 | 73.62 - 74.06 |
| Low: | 71.1 - 71.73 | 71.73 - 72.3 |
| Close: | 71.93 - 72.91 | 72.91 - 73.8 |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Sun, 06 Oct 2024
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Fri, 04 Oct 2024
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings) - Benzinga
Fri, 04 Oct 2024
Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $108.00 at Royal Bank of Canada - MarketBeat
Wed, 02 Oct 2024
50,000 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Bought by Ghisallo Capital Management LLC - MarketBeat
Sun, 22 Sep 2024
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 106 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 96.8 (%) |
| Shares Short | 2,570 (K) |
| Shares Short P.Month | 2,540 (K) |
| EPS | -0.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.84 |
| Profit Margin | -15 % |
| Operating Margin | -17.2 % |
| Return on Assets (ttm) | -7 % |
| Return on Equity (ttm) | -9.7 % |
| Qtrly Rev. Growth | 45.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.34 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -83.25 |
| PEG Ratio | -0.4 |
| Price to Book value | 6.6 |
| Price to Sales | 13.4 |
| Price to Cash Flow | -124.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|